Vincerx Pharma (VINC) to Implement Cost-Controls
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- Key things to know ahead of SK Hynix’s blockbuster US listing
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943
December 4, 2024 6:45 AM ESTPALO ALTO, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced plans to implement cost-controls and explore strategic alternatives to support advancing the Phase 1 study of VIP943, the Companys novel CD123-targeted antibody-drug conjugate (ADC) developed with the Companys next-generation VersAptx... More
